Cytek Biosciences, Inc. Common Stock (CTKB) Technical Analysis
$5.65
Market is closed - opens 7 PM, 28 Sep 2026
Insights
- Cytek Biosciences Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Cytek Biosciences Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Cytek Biosciences Inc. stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Cytek Biosciences Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 71.86 | Sell |
Stochastic | 85.35, 88.03 | Sell |
Ultimate Oscillator | 63.7 | Neutral |
Stochastic Relative Strength Index | 92.71, 95.83 | Sell |
Moving Average Convergence Divergence | 0.28, 0.19 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.32 | Buy |
20 | 4.99 | Buy |
50 | 4.71 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.37 | Buy |
20 | 5.12 | Buy |
50 | 4.81 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.33 | Buy |
20 | 5.1 | Buy |
50 | 4.83 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.69 | Buy |
20 | 5.46 | Buy |
50 | 5.11 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 5.79 | Buy |
20 | 5.64 | Buy |
50 | 5.31 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 6.23 |
Resistance L2 | 6.03 |
Resistance L1 | 5.88 |
Pivot Point | 5.68 |
Support L1 | 5.53 |
Support L2 | 5.33 |
Support L3 | 5.18 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.